Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23025720 | 0.83 | PDE4D (0.50) | PDE4DKDM4EPOLBMAPTMEN1 | |
| SCHEMBL7277080 | 0.81 | PDE4D (0.44) | PDE4DKDM4EALPLPOLBL3MBTL1 | |
| SCHEMBL5648877 | 0.81 | KDM4E (0.46) | PDE4DKDM4EPOLBMAPTMEN1 | |
| SCHEMBL15897055 | 0.80 | PDE4D (0.43) | PDE4DKDM4EPOLBL3MBTL1MAPT | |
| SCHEMBL11368014 | 0.80 | ALDH1A1 (0.50) | PDE4DKDM4EPOLBMAPTMEN1 | |
| SCHEMBL5906562 | 0.80 | PDE4D (0.43) | PDE4DKDM4EPOLBMAPTMEN1 | |
| SCHEMBL1412491 | 0.79 | PDE4D (0.42) | PDE4DKDM4EPOLBL3MBTL1MAPT | |
| SCHEMBL11528604 | 0.79 | PDE4D (0.42) | PDE4DKDM4EALPLPOLBMAPT | |
| SCHEMBL5648880 | 0.79 | KDM4E (0.47) | PDE4DKDM4EPOLBMAPTMEN1 | |
| SCHEMBL1930598 | 0.77 | PDE4D (0.41) | PDE4DKDM4EPOLBMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186441-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2025-06-12 | — | — | US | disclosed |
| US-12213976-B2 | Compounds and methods for treating oxalate-related diseases | OXALURX, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20230110495-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230110495-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11504367-B2 | Compounds and methods for treating oxalate-related diseases | OXALURX, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-11389456-B2 | Compounds and methods for treating oxalate-related diseases | OXALURX, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-4017490-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | Oxalurx, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20210052586-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2021-02-25 | — | — | US | disclosed |
| WO-2021035196-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. (US) | 2021-02-25 | — | — | WO | disclosed |
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2020-12-17 | — | — | US | disclosed |
| WO-2019165159-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| US-7956070-B2 | Piperidines as chemokine modulators (CCR) | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| US-20070054924-A1 | Novel piperidines as chemokine modulators (ccr) | ASTRAZENECA AB (SE) | 2007-03-08 | — | — | US | disclosed |
| EP-1713772-A1 | NOVEL PIPERIDINES AS CHEMOKINE MODULATORS (CCR) | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005073192-A1 | NOVEL PIPERIDINES AS CHEMOKINE MODULATORS (CCR) | ASTRAZENECA AB (SE) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054924-A1 | Novel piperidines as chemokine modulators (ccr) | CCR3, CCR1, CCR4 | PDE4D 82/4885KDM4E 3873/4885ALPL 4870/4885 |
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | XDH, PNPO, LOX | PDE4D 1687/4885KDM4E 3780/4885ALPL 576/4885 |
| US-20210052586-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | XDH, PNPO, OAT | PDE4D 1661/4885KDM4E 3804/4885ALPL 585/4885 |
| US-11389456-B2 | Compounds and methods for treating oxalate-related diseases | XDH, PNPO, LOX | PDE4D 1687/4885KDM4E 3780/4885ALPL 576/4885 |
| US-11504367-B2 | Compounds and methods for treating oxalate-related diseases | XDH, PNPO, OAT | PDE4D 1661/4885KDM4E 3804/4885ALPL 585/4885 |
| US-20250186441-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | XDH, PNPO, OAT | PDE4D 1661/4885KDM4E 3804/4885ALPL 585/4885 |
| US-20230110495-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | XDH, PNPO, OAT | PDE4D 1661/4885KDM4E 3804/4885ALPL 585/4885 |
| US-12213976-B2 | Compounds and methods for treating oxalate-related diseases | XDH, PNPO, OAT | PDE4D 1661/4885KDM4E 3804/4885ALPL 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.